Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Growth Hormone Receptor Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Growth Hormone Receptor Agonist Market: Competitive Landscape, Pipeline, and Market Analysis 2023
Growth hormone receptor (GHR) is a transmembrane protein consisting of 620 amino acids. The receptor is part of the Type I cytokine receptor family of receptors. This gene encodes a protein that is a transmembrane receptor for growth hormone. The binding of growth hormone to the receptor leads to the reorientation of a pre-assembled receptor dimer dimerization and the activation of an intra- and intercellular signal transduction pathway leading to growth agonist mimics the action as performed by the growth hormone in the body. The mechanism of action (MOA) of the GHR agonist is by binding GHR dimerizes and interacts with Janus kinase 2 (JAK2), subsequently leading to tyrosine phosphorylation of JAK2 and the GH receptor.
The signal transducer activator of the transcription (STAT) pathway is initiated, where transcription factors such as STAT1, STAT3, and STAT5 are translocated into the nucleus to stimulate target gene transcription. At the epiphysis or growth plate, growth hormone increases linear growth by promoting differentiation of pre-chondrocytes and expansion of osteoblasts and binding to its receptor in the liver and cartilage promotes the production of IGF-1, which acts on type 1 IGF receptors to also stimulate linear growth. GHR Agonists are used in the treatment of bone diseases, dwarfism, endocrine system diseases, brain diseases, pituitary diseases, growth diseases, heart diseases, gonadal disorders, infertility, and obesity among others. Increased prevalence of bone and endocrine disorders and increased R&D investment are the key drivers for the GHR Agonist market. For instance, according to the National Organization for Rare Disorders 2021, it has been estimated that achondroplasia is the most commonly occurring abnormality of bone growth (skeletal dysplasia), occurring in approximately 1 in 20,000-30,000 live births. The introduction of newer products by market players may look for opportunities that have a big impact on comprehensive research and development in GHR Agonist. For instance, Novo Nordisk launched Norditropin (Somatropin) for the treatment of growth hormone deficiencies in children and adults. Moreover, to address the difficulties in therapy, numerous market participants are developing innovative compounds. For instance, Lateral Pharma’s LAT8881 for the indication of neuropathic pain is under the various stages of clinical studies.
Key Market Developments:
Approved Drug Molecules and Brand Names for GHR Agonist:
Drugs under the Pipeline for GHR Agonist:
Clinical Activity and Developments of GHR Agonist:
Up until July 2023, there will be about 41 companies with over 34 compounds that focus on various forms of bone diseases and CNS disorders. For these molecules, more than 60 clinical trials are being conducted and the majority are in phase-2, phase-3 clinical trials by the players across the globe. For instance,
|
Molecule Name |
Number of Studies |
|
Sogroya (Somapacitan) |
19 |
|
Tev-Tropin (JR-401S) |
9 |
|
Macrilen (Macimorelin) |
8 |
|
Somavaratan (VRS-317) |
8 |
|
LAT8881 |
5 |
The molecules such as Ngenla (Somatrogon-Ghla) developed by Pfizer in global collaboration with OPKO Health for the line of treatment for the treatment of patients aged three years and older who have growth failure due to inadequate secretion of endogenous growth hormone. Ascendis Pharma’s Skytrofa (Lonapegsomatropin-Tcgd) for pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone. Moreover, Genentech’s Nutropin AQ (Somatropin) for the treatment of children with growth failure due to growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS), and chronic kidney disease (CKD) up to the time of renal transplantation and approved for the treatment of adults with either childhood-onset or adult-onset GHD.
Skytrofa (Lonapegsomatropin) is the only FDA-approved once-weekly treatment for pediatric patients one year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone. Till February 2022 Skytrofa prescriptions were written by approximately 263 prescribers, including 44% writing prescriptions for multiple patients in the USA. The increasing prevalence of endocrine-related disorders, such as adrenal insufficiency, Cushing's disease, gigantism, hypothyroidism, hyperthyroidism, and also some bone diseases like dwarfism represents one of the key factors driving the growth of the GHR agonist market. Furthermore, the increasing health consciousness and awareness regarding the benefits of timely testing is providing a boost to market growth. Periodic testing minimizes the risks of developing complications or aggravation of the disorder, especially in elderly patients. For instance, according to American Thyroid Association 2023, more than 12% of the US population will develop a thyroid condition during their lifetime and an estimated 20 million Americans have some form of thyroid disease is expected to create a lucrative opportunity for the GHR Agonist market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
Ngenla (Somatrogon-Ghla), Skytrofa (Lonapegsomatropin-Tcgd), and Norditropin (Somatropin), are the few FDA-approved GHR Agonist.
Novo Nordisk, EMD Serono, Ipsen, Roche, and Pfizer are few leading market players in GHR Agonist Market.
Bone disorders, dwarfism, endocrine system diseases, brain diseases, pituitary diseases, growth diseases, heart diseases, gonadal disorder, infertility, obesity, etc are the major indication of GHR agonists.
There are a total of 22 molecules that are in the Phase-1, Phase-2 and Phase-3 clinical development for GHR agonist.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.